Cutaneous dermal Ia+ cells are capable of initiating delayed type hypersensitivity responses

Y Tse1, K D Cooper

  • 1Department of Dermatology, University of Michigan Medical Center, Ann Arbor.

Insights

Dermal cells, specifically Ia+ cells, can initiate skin immune responses similar to epidermal Langerhans cells (LC). This finding is crucial for understanding how the skin

Area of Science:

  • Immunology
  • Dermatology
  • Cell Biology

Background:

  • Langerhans cells (LC) in the epidermis are key for skin T-cell immunity.
  • The role of dermal cells in initiating T-cell responses was previously unclear.

Purpose of the Study:

  • To investigate if dermal cells can initiate T-cell-mediated delayed-type hypersensitivity (DTH) responses in vivo.
  • To identify specific dermal cell populations responsible for initiating DTH.

Main Methods:

  • Prepared mouse dermal cell suspensions using dispase to avoid hair follicle contamination.
  • Haptenated dermal cells with trinitrophenyl (TNP) and injected them intradermally into mice.
  • Assessed contact hypersensitivity (CHS) by measuring ear swelling after epicutaneous TNP painting.

Main Results:

  • Dermal cell injections induced significant CHS, indicated by ear swelling (53 +/- 8 mm X 10(-3)).
  • Dermal cells depleted of Ia+ cells showed a markedly reduced CHS response (10 +/- 1 mm X 10(-3)).
  • Hair follicles, when contaminated, also contained Ia+ cells that initiated CHS.

Conclusions:

  • Perivascular dendritic Ia+ cells in the dermis, like epidermal LC, can initiate T-cell-mediated CHS in vivo.
  • These dermal Ia+ cells are important for antigen presentation to T cells in the skin.
  • The findings highlight the significant role of dermal immune cells in skin sensitization and immune responses.

Related Concept Videos

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Allergic Drug Reactions01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
Hypersensitivities01:30

Hypersensitivities

Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions01:29

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...